

# **One Year Post Exclusivity Adverse Event Review: Celebrex® (celecoxib)**

**Pediatric Advisory Committee Meeting  
March 25, 2008**

**Hari Cheryl Sachs, MD, FAAP; Medical Officer  
Pediatric and Maternal Health Staff  
Office of New Drugs  
Food and Drug Administration**



# Outline

- **Background Drug Information**
- **Drug Use Trends**
- **Pediatric Exclusivity Studies**
- **Pediatric Exclusivity Labeling Changes**
- **Additional Relevant Safety Labeling**
- **Adverse Events**
  - Since approval
  - One-year post exclusivity
- **Summary**

# Background Drug Information

- **Drug:** Celebrex<sup>®</sup> (celecoxib)
- **Therapeutic Category:** Non-Steroidal Anti-inflammatory Drug (NSAID)
- **Sponsor:** G.D. Searle
- **Original Market Approval:** December 31, 1998
- **Pediatric Exclusivity Granted:** August 23, 2006
- **JRA Approval:** December 15, 2006

# Background Drug Information

## Adults only:

- Relief of the signs and symptoms of:
  - Osteoarthritis
  - Rheumatoid arthritis
  - Ankylosing Spondylitis
- Management of acute pain
- Treatment of primary dysmenorrhea
- Adjunctive treatment in Familial Adenomatous Polyposis (FAP)

## Pediatric patients:

- Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) 2 years and older

# Background Drug Information

## Dosage:

- **Adult patients:**
  - OA 200 mg/day as one dose or 100 mg BID
  - RA: 100 to 200 mg BID
  - Ankylosing Spondylitis: up to 400 mg per day
  - Acute Pain or Primary dysmenorrhea: 400 mg initially, then 200 mg BID prn
  - FAP: 400 mg BID with food
- **Pediatric patients:**
  - 10 to 25 kg: 50 mg BID
  - >25 kg 100 mg BID

# Drug Use Trends: celecoxib

## Drugs Selected for Review:

leflunomide + NSAID's

celecoxib

etodolac

flurbiprofen

indomethacin

meclofenamate

meloxicam

nabumetone

piroxicam

sulindac

valdecoxib

diclofenac

fenoprofen

ibuprofen

ketoprofen

mefenamic acid

naproxen

oxaprozin

rofecoxib

tolmetin

# Drug Use Trends: celecoxib

**Primary Use:** Outpatient setting (91%)<sup>1</sup>

Retail sales channels (65%)

Mail order (26%)

Non-retail channels (9%)

**Majority of use in adults (>99%)<sup>2</sup>**

3<sup>rd</sup> in terms of prescription volume for selected products

**Trends in prescription volume (adults)<sup>2</sup>**

From baseline (Sept 2004 to Aug 2005) to post exclusivity period (Sept 2006 to Aug 2007) decreased by 20%

Slight increase pre- (Sept 2005 to Aug 2006) and post-exclusivity period (Sept 2006 to Aug 2007) 2%

<sup>1</sup>IMS Health, IMS Nationals Sales Perspectives™, Sept 2006 to August 2007, Data extracted Jan 2008

<sup>2</sup>Verispan, LLC, Vector One® National (VONA), Data extracted Jan 2008

# Drug Use Trends: celecoxib

**Celecoxib 8<sup>th</sup> in terms of prescription volume for selected products in pediatric patients**

## **Trends in prescription volume (pediatric)<sup>2</sup>**

- Baseline (Sept 2004 to Aug 2005) to post exclusivity period (Sept 2006 to Aug 2007): 28% decrease
- Pre- (Sept 2005 to Aug 2006) and post-exclusivity period (Sept 2005 to Aug 2006): 3% increase

## **Prescriber Specialty<sup>2</sup>**


General practice (33 to 35%)

Internal Medicine (25 to 26%)

Pediatrics (<1%)

# Drug Use Trends: celecoxib

Figure 3: Total number of dispensed prescriptions for selected anti-rheumatic drug market\* (minus ibuprofen, naproxen) in the pediatric population (ages 0-18), September 1, 2004 - August 31, 2007



# Drug Use Trends: celecoxib

## Pediatric Indications for Use<sup>3</sup>

sprains and strains (33%)

osteocondropathy (16%)

related to rheumatoid arthritis/other polyarthropathy (4%)

## Duration of Use (pediatric patients)<sup>3</sup>

Baseline (Sept 2004 to Aug 2005): 8 to 15 days (28%)  
and >91 days (17%)

Pre-exclusivity (Sept 2005 to Aug 2006): 16 to 30 days  
(36%)

Post-exclusivity (Sept 2006 to Aug 2007): 16 to 30 days  
(67%)

<sup>3</sup>Verispan LLC, Verispan Physician Drug and Diagnosis Audit, extracted Jan 2008



[CDER Home](#)

[About CDER](#)

[Drug Information](#)

[Regulatory Guidance](#)

[CDER Calendar](#)

[Specific Audiences](#)

[CDER Archives](#)

Search



powered by Google™

Summaries of Medical and Clinical Pharmacology Reviews  
of Pediatric Studies  
as of January 15, 2008

Total Number of Drugs with Summaries Posted: 88

Summaries of Medical and Clinical Pharmacology Reviews

Drug	Sponsor	Review Summary	
Carvedilol - Coreg	GlaxoSmithKline	<a href="#">Medical</a>	<a href="#">Clinical Pharmacology</a>
Celecoxib - Celebrex	G.D. Searle	<a href="#">Medical</a>	<a href="#">Clinical Pharmacology</a>
Ciprofloxacin - Ciloxan	Alcon	<a href="#">Medical</a>	None*
Ciprofloxacin - Cipro	Bayer	<a href="#">Medical</a>	<a href="#">Clinical Pharmacology</a>



# Pediatric Exclusivity Studies: celecoxib

- Relative bioavailability study: capsule and suspension (adults, n=195)
  - $C_{\max}$  50% higher (capsule vs. suspension)
  - AUC 15% higher (capsule vs. suspension)
- Relative bioavailability study: intact capsule and capsule sprinkled on applesauce (adults)
  - Similar  $C_{\max}$  and AUC
- Clinical efficacy study of celecoxib suspension (100 mg/5 mL)

# Pediatric Exclusivity Study: celecoxib

- Mean clearance lower in children 2 to 5 years (32% lower) and >5 to 11 years (26%) compared with adults
- Mean clearance in adolescents (>11 to <17 years) similar to adults
- 3-fold increase in body weight yielded a 50% increase in clearance
- Additional considerations in dose selection:
  - Exposure-response analysis suggests greater percentage of early responders achievable with higher dose
  - matching exposures to the minimum doses (6 mg/kg) found to be non-inferior to naproxen (efficacy boundary)
  - Achieving exposures less than those found from doses up to 12 mg/kg of the suspension during JRA trial (safety boundary)

# Pediatric Exclusivity Studies: Labeling changes

## Pharmacokinetics: Special Populations- Pediatrics

- pK findings in 152 JRA patients  $\geq 10$ kg
- Oral clearance increases less than proportionally with increasing body weight
- Compared with 70 kg adult:
  - 10 kg patient have 40% lower clearance
  - 25 kg patient have 24% lower clearance
- Similar plasma concentrations should be achieved by:
  - 50 mg BID to  $\geq 12$  to  $\leq 25$ kg
  - 100 mg BID  $>25$  kg

**Dosage and Administration:** JRA 2 years and older

# Pediatric Exclusivity Studies: Efficacy celecoxib

- Randomized, double-blind, active control study of celecoxib 6 or 12 mg/kg/day with naproxen 15 mg/kg/day
- Primary outcome: percent patients achieving a JRA definition of improvement 30 (DOI-30)
- Improvements seen in all components of JRA DOI-30
- Established non-inferiority of both doses to naproxen

# Labeling Changes: Efficacy of celecoxib

## Clinical Studies (JRA)

- 12 week, non-inferiority trial (n= 242)
- Response rates (JRA DOI 30) at week 12
  - Celecoxib 6 mg/kg divided BID: 69%
  - Celecoxib 12 mg/kg divided BID 80%
  - Naproxen 15 mg/kg divided BID: 67%
- Safety and efficacy not studied beyond 6 months
- Cardiovascular toxicity not evaluated

**Indications and Usage:** relief of signs and symptoms of JRA 2 years and older

## Precautions: Pediatric Use:

- Reiterates approval and describes pediatric trial and limitations
- Patients with systemic onset JRA appear to be at risk of abnormal coagulation tests

# Pediatric Exclusivity Study: Safety celecoxib

No deaths in either 12 wk PCT (n =242) or OL extension

Data available for 6 months of treatment (n= 202)

Most common AEs: GI, infections and infestations, and nervous system disorder

Serious AEs:

- in low-dose, more frequent than naproxen arm, but no dose-response seen
- did not differ from AE profile of NSAIDs

# **Pediatric Exclusivity Study: Safety Labeling Changes celecoxib**

## **Adverse events from JRA study**

- Most common (>5%): headache, fever, upper abdominal pain, cough, nasopharyngitis, lower abdominal pain, nausea, arthralgia, diarrhea and vomiting
- No observable deleterious effect on growth compared with naproxen
- No exacerbations of uveitis or systemic JRA
- Includes table of AE

# Postmarketing Commitments: celecoxib

- Short-term study of gastrointestinal toxicity and hypertension risk (6-week, randomized, open-label trial in 200 patients celecoxib vs. naproxen)
- Enhanced pharmacovigilance:
  - Active surveillance of pediatric networks
  - Prospective observational registry (400 patients)
  - Creation of Independent Pediatric expert panel

# **Additional Relevant Safety Labeling: celecoxib**

## **Boxed Warning (class):**

- Increase risk of serious, potentially fatal cardiovascular thrombotic events (MI, stroke)
- Increased risk of serious gastrointestinal AEs, including bleeding, ulceration and perforation

## **Contraindication**

- Allergy-type reaction to sulfonamide
- Asthma, urticaria or allergic-reaction after NSAID or aspirin

# Additional Relevant Safety Labeling: celecoxib

## Warnings

- Cardiovascular thrombotic events with chronic use
- Hypertension (class)
- Congestive heart failure and edema
- Renal effects (class)- renal papillary necrosis and other renal injury
- Advanced renal disease- not recommended, monitor
- Anaphylactoid reactions (class)
- Skin reactions such as SJS, TENS, exfoliative : related to sulfonamide
- Avoid in late pregnancy (premature closure of ductus)
- **Bolded:** treatment in FAP not shown to reduce risk of GI cancer, prophylactic colectomy or other FAP-related surgery

# Additional Relevant Safety Labeling: celecoxib

## Precautions

- General: Not a substitute for corticosteroids; avoid with non-aspirin NSAID, may diminish ability to detect fever or inflammation
- Hepatic: borderline elevations 15%, serious 1%
- Hematological: anemia
- Systemic JRA- use with caution, including DIC
- Asthma- severe bronchospasm in aspirin-sensitive asthma
- Laboratory tests: Monitor for signs and symptoms GI bleeding, periodic CBC and chemistry profile

Note: warnings and precautions reiterated in information for patients, MedGuide

# Additional Relevant Safety Labeling: celecoxib

**Pregnancy Category C:** increased risk of VSD, bony abnormality (rabbits)

**Nursing:** excreted in animals, limited data indicates also in humans

**Overdosage:** up to 2400 mg, no serious toxicity

Symptoms usually limited to lethargy, drowsiness, nausea, vomiting and epigastric pain

GI bleeding

Rare: hypertension, acute renal failure, respiratory depression, and coma

Anaphylaxis

# Previous OSE Reviews: Celecoxib

- Hepatotoxicity, GI bleeding and death (7/1999)
- Fatal GI bleeding, obstruction, perforation or stenosis (12/2000)
- Thrombotic Vascular events (2/2001, 12/2002, 2/2005)
- Hearing loss (6/2001)
- Aseptic Meningitis (12/2002)
- Myopathy/Rhabdomyolysis (6/2002)
- Ischemic colitis (6/2003)
- Metabolic acidosis, nephrolithiasis, bony fractures (6/2006)

# Adverse Event Reports since Approval (Dec 1998 to Sept 23, 2007): celecoxib

Raw counts*	All reports (US)	Serious (US)	Death (US)
All ages	28186 (24762)	18781 (15425)	2372 (1791)
Adults ( $\geq 17$ )	18173 (15316)	12309 (9509)	1542 (1038)
Pediatrics (0-16)	94 (70)	77 (53)	13 (11)
Unknown Age	9919 (9376)	6395 (5863)	817 (742)

\*includes duplicates and unknown ages

\*\*Serious AEs per regulatory definition (CFR 314.80) include death, life-threatening, hospitalization (initial or prolonged), disability & congenital anomaly

# Fatal Adverse Events since Approval: celecoxib

\*Raw counts: 13

Since approval (Dec 1998) to one-year exclusivity  
period (Aug 2006): 8

hands on review: 3 pediatric cases

One-year post exclusivity period (Aug 2006 to Sept  
2007): 5\*

hands on review: 2 pediatric cases

\*includes duplicates, events in adults or events  
unrelated to celecoxib

# Fatal Adverse Events (Dec 1998 to August 2006): celecoxib

8 y/o female with endstage renal carcinoma, congestive heart failure and cardiomyopathy (multiple medications including inteferon-alpha, vinblastine, celecoxib)

9 y/o male with medulloblastoma and intracranial hemorrhage (multiple medications including celecoxib, thalidomide)

Adolescent male with completed suicide 6 days after starting celecoxib (concomitant medications: salmeterol, fluticasone and “unknown patch.”)

Labeling: CHF (warnings), intracranial hemorrhage (boxed warning), suicide (adverse events)

# Adverse Event Reports during One-Year Post Exclusivity Period (8/23/2006 to 9/23/2007): celecoxib

Raw counts*	All reports (US)	Serious (US)	Death (US)
All ages	6144 (5854)	6127 (5838)	915 (888)
Adults ( $\geq 17$ )	3211 (2990)	2910 (2847)	501 (479)
Pediatrics (0-16)	19 (13)	19 (13)	5 (5)
Unknown Age	2914 (2851)	2910 (2847)	409 (404)

\*includes duplicates and unknown ages

\*\*Serious AEs per regulatory definition (CFR 314.80) include death, life-threatening, hospitalization (initial or prolonged), disability & congenital anomaly

# Adverse Events during Pediatric Exclusivity Period

10 unduplicated cases:

- Fatalities (n=2) during pilot study of newly diagnosed Ewing's sarcoma
- nonfatal AEs (n=8)
  - Dyspnea (2)
  - Palpitations (2)
  - Pulmonary embolism (2)
  - Single reports of bullous eruptions, intracranial hemorrhage, pancytopenia, GI bleed, chest pain, blood clots

# Fatal Adverse Events during Pediatric Exclusivity Period (n=2)

12 y/o female with newly diagnosed metastatic Ewing's Sarcoma admitted for fever, neutropenia, fluid overload; required aggressive mechanical ventilation and inotrope, ultimately developed GI bleed, sepsis, renal and hepatic failure and died

16 y/o female with newly diagnosed metastatic Ewing's Sarcoma, developed radiation pneumonitis, pancytopenia, pericardial effusion and pulmonary hypertension, s/p pericardiocentesis, recurrent cardiac arrest and died

Possible confounders: chemotherapy, radiation therapy, underlying disease. Note off-label indications

# Summary: celecoxib

- Labeling updated with new pediatric indication (JRA), dose, and limitations of study
- AEs incorporated: increased risk of DIC, common AEs (GI, infectious symptoms, arthralgia)
- No new unexpected pediatric AEs were identified for celecoxib from the postmarketing reports reviewed for this report.
- Data from studies focusing on safety assessments during the Postmarket period are still pending and the proposed studies will be presented by the sponsor today.

A follow up report will be presented to the AC after the Post Marketing Commitment studies have been completed.  
Does the Advisory Committee concur with this plan?

# Acknowledgements

## OSE

Mark Avigan

Laura Governale

Solomon Iyasu

Lauren Lee

Joann Lee

Ann McMahon

## PMHS

Lisa Mathis

Denise Pica-Branco

## DAARP

Jeff Siegel

Sharon Hertz

## OPT

Debbie Avant

Judith Cope

Dianne Murphy